LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

Home・Lista de Ações・Avidity Biosciences Inc

Avidity Biosciences Inc

Fechado

SetorSaúde

15.05

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

15.05

Máximo

15.05

Indicadores-chave
By Trading Economics
Rendimento	-63M -237M
Vendas	-12M 860K
EPS	-1.27
Margem de lucro	-27,569.884
Funcionários	511
EBITDA	-59M -232M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-0.1% downside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-9B 2.3B
Abertura anterior	15.05
Fecho anterior	15.05

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

25.575 / 32.65 Suporte e Resistência

Avidity Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de mar. de 2026, 23:01 UTC

Ganhos

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5 de mar. de 2026, 21:54 UTC

Ganhos

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5 de mar. de 2026, 21:35 UTC

Grandes Movimentos do Mercado

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6 de mar. de 2026, 00:00 UTC

Notícias Principais

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5 de mar. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5 de mar. de 2026, 23:33 UTC

Conversa de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5 de mar. de 2026, 23:27 UTC

Conversa de Mercado

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5 de mar. de 2026, 22:54 UTC

Conversa de Mercado

Ganhos

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5 de mar. de 2026, 22:50 UTC

Conversa de Mercado

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5 de mar. de 2026, 22:48 UTC

Ganhos

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5 de mar. de 2026, 22:46 UTC

Ganhos

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5 de mar. de 2026, 22:44 UTC

Ganhos

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 de mar. de 2026, 21:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de mar. de 2026, 21:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de mar. de 2026, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

5 de mar. de 2026, 21:35 UTC

Ganhos

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 de mar. de 2026, 21:32 UTC

Ganhos

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 de mar. de 2026, 21:26 UTC

Ganhos

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5 de mar. de 2026, 21:24 UTC

Ganhos

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5 de mar. de 2026, 21:23 UTC

Ganhos

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5 de mar. de 2026, 21:22 UTC

Ganhos

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 de mar. de 2026, 21:21 UTC

Ganhos

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5 de mar. de 2026, 21:21 UTC

Ganhos

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5 de mar. de 2026, 21:20 UTC

Ganhos

Costco February Net Sales Were $21.69 B >COST

5 de mar. de 2026, 21:20 UTC

Ganhos

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 de mar. de 2026, 21:20 UTC

Ganhos

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 de mar. de 2026, 21:19 UTC

Ganhos

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5 de mar. de 2026, 21:18 UTC

Ganhos

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5 de mar. de 2026, 21:18 UTC

Ganhos

Costco 2Q Same-Store Sales Up 7.4% >COST

5 de mar. de 2026, 21:15 UTC

Ganhos

Costco 2Q EPS $4.58 >COST

Comparação entre Pares

Variação de preço

Avidity Biosciences Inc Previsão

Preço-alvo

By TipRanks

-0.1% parte inferior

Previsão para 12 meses

Média 72.75 USD -0.1%

Máximo 75 USD

Mínimo 72 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Avidity Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Avidity Biosciences Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

25.575 / 32.65Suporte e Resistência

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Recent bearish events outweigh bullish events.

Informação Financeira

Sobre Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.